Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ibrilatazar |
| Synonyms | |
| Therapy Description |
Ibrilatazar is a lipid analog that inhibits mTOR and DHFR, potentially resulting in decreased tumor cell proliferation and increased tumor cell death (Cancer Res April 15, 2012 72:922, PMID: 32397857). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ibrilatazar | ABTL-0812|ABTL0812|ABTL 0812|LP10218|LP 10218|SCLN-0812|2-Hydroxylinoleic Acid | mTOR Inhibitor 51 | Ibrilatazar is a lipid analog that inhibits mTOR and DHFR, potentially resulting in decreased tumor cell proliferation and increased tumor cell death (Cancer Res April 15, 2012 72:922, PMID: 32397857). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|